However, in vitro studies on ovarian cancer cell lines were able to show increased sensitivity to docetaxel when combined with the monoclonal antibody MAb C595 and in vivo studies using a MUC1/docetaxel conjugate showed higher cytotoxicity than docetaxel alone in multidrug resistant ovarian cancer [29,30]. This evidence concerns the gene MUC1 and ovarian carcinoma.